Evidence map›Paper›PMID 32435407›Full record

ArticleACS medicinal chemistry letters2020

Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.

Baris Kucukkaraduman, Can Turk, Anna L Fallacara, Murat Isbilen, Kerem M Senses, Zeynep O Ayyildiz, Muhammad W Akbar, Michal Lotem, Maurizio Botta, Ali O Gure

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Baris KucukkaradumanDepartment of Molecular Biology and Genetics, Bilkent University, Ankara 06800, Turkey.
Can TurkFaculty of Medicine, Department of Medical Microbiology, Lokman Hekim University, Ankara 06510, Turkey.
Anna L FallacaraDepartment of Biotechnology, Chemistry and Pharmacy, "Department of Excellence 2018-2022", University of Siena, Via Aldo Moro 2, Siena 53100, Italy.
Murat IsbilenDNAFect Genetics Consulting R&D and Biotechnology Inc., Kocaeli 41470, Turkey.
Kerem M SensesDepartment of Molecular Biology and Genetics, Zonguldak Bulent Ecevit University, Zonguldak 67100, Turkey.
Zeynep O AyyildizDepartment of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey.
Muhammad W AkbarDepartment of Molecular Biology and Genetics, Bilkent University, Ankara 06800, Turkey.
Michal LotemSharett Institute of Oncology, Hadassah Hebrew University Hospital, Ein Karem Campus, Jerusalem 91120, Israel.
Maurizio BottaDepartment of Biotechnology, Chemistry and Pharmacy, "Department of Excellence 2018-2022", University of Siena, Via Aldo Moro 2, Siena 53100, Italy.
Ali O GureDepartment of Molecular Biology and Genetics, Bilkent University, Ankara 06800, Turkey.
Bilkent University · TRUniversity of Siena · ITBülent Ecevit University · TRDokuz Eylül University · TRHadassah Medical Center · ILLokman Hekim Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a highly aggressive cancer with poor prognosis. Although more than 80% of melanomas harbor an activating mutation in genes within the MAPK pathway, which are mutually exclusive, usefulness of therapies targeting MAPK pathway are impeded by innate and/or acquired resistance in most patients. In this study, using melanoma cells, we report the efficacy of a recently developed pyrazolo[3,4-

Identifiers

PMID32435407
PMCPMC7236227
OpenAlexW3007587469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.